| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_72a496d0fb758c10d49d24509ee2f9de |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61J1-12 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C01B23-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2292
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61J1-1468 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61J1-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C01B23-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61J1-14 |
| filingDate |
2015-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d5ac9a286838cd65bf4a53d9f444eb0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24f0a42f7c928148f185d9a61aa62671
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80fbea2fc67b6e2bcfc5501578f16480
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42022c1d666439c824dc15370cec4fd3 |
| publicationDate |
2020-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10744088-B2 |
| titleOfInvention |
Method for preparing ophthalmic preparation containing thymosin beta-4 |
| abstract |
The present invention relates to a method for manufacturing an ophthalmic preparation comprising thymosin β4. According to the inventive method, the manufacture of an ophthalmic preparation comprising thymosin β4 is carried out in the presence of an inert gas, thus the contact of thymosin β4 with oxygen is blocked and the oxidation of thymosin β4 can be prevented and the pharmacological activity of thymosin β4 maintains for long-term period. Therefore, the ophthalmic preparation prepared by the inventive method can maintain the pharmacological activity of thymosin β4 in a stable state for a long time. |
| priorityDate |
2015-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |